Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas
Author Information
Author(s): Loussouarn D, Campion L, Sagan C, Frenel J-S, Dravet F, Classe J-M, Pioud-Martigny R, Berton-Rigaud D, Bourbouloux E, Mosnier J-F, Bataille F-R, Campone M
Primary Institution: University Hospital of Nantes, Nantes, France
Hypothesis
What is the prognostic significance of syndecan-1 expression in invasive ductal breast carcinomas?
Conclusion
The loss of syndecan-1 epithelial expression is a strong prognostic indicator in breast carcinomas.
Supporting Evidence
- 61.25% of patients showed exclusive epithelial expression of syndecan-1.
- 30% of patients had exclusive stromal expression of syndecan-1.
- Loss of epithelial syndecan-1 expression correlated with high grade of malignancy.
- Loss of epithelial syndecan-1 expression was the only prognostic indicator in multivariate analysis.
Takeaway
This study found that when breast cancer cells lose a specific protein called syndecan-1, it can mean the cancer is more aggressive and harder to treat.
Methodology
The study involved a cohort of 80 patients with invasive ductal breast carcinomas, using tissue microarrays and immunohistochemistry to assess syndecan-1 expression.
Limitations
The study was limited to a single histological type of breast carcinoma and lacked chemotherapy treatment in the cohort.
Participant Demographics
Patients had a mean age of 72.7 years, with a range from 44 to 95 years.
Statistical Information
P-Value
P<0.001
Confidence Interval
95% CI: 86–99%
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website